CB2 Insights

CB2 takes huge leap forward signing agreement with Premier Health Group

CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver on Skype from Toronto to share news the company has signed an agreement with the British Columbia based Premier Health Group to use the industry’s only medical cannabis-specific Clinical Decision Support tool.

This deal gives CB2 access to 4600 physicians and data gathered from over 300 thousand patients. 

Quick facts: CB2 Insights

Price: $0.17

Market: CSE
Market Cap: $12.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said...



Cb2 Insights signs letter of Intent with UK company, Drug Science for...

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21 Sekar told Proactive about that project and...

4 weeks, 2 days ago

2 min read